ArticleMedical oncology (Northwood, London, England)2025
Evaluation of the efficacy and safety of HyperArc stereotactic radiotherapy for the treatment of lung cancer brain metastasis.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case Report: Simultaneous stereotactic re-irradiation using HyperArc for 44 brain metastases after whole-brain radiotherapy.Frontiers in oncology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study assessed the efficacy and safety of HyperArc (HA) stereotactic radiotherapy (SRT) in 48 patients with lung cancer brain metastases (LCBM) while identifying prognostic factors and high-risk predictors for symptomatic cerebral radiation necrosis (sCRN). We enrolled 48 patients diagnosed with LCBM at the People's Hospital Affiliated to Jiangsu University between February 2021 and February 2025, assigning 44 to the SRT group and 4 to the WBRT-boost group. Clinical data were collected, and all patients underwent HA stereotactic radiotherapy. The WBRT-boost group additionally received a local HA boost. Prescription doses of 24-30 Gy were administered in 3-5 fractions at 5 fractions weekly, tailored to lesion characteristics. We evaluated both the efficacy and safety of HA treatment for LCBM. The 1-year overall survival (OS), intracranial distant progression-free survival (iDPFS), and intracranial local progression-free survival (iLPFS) rates for the entire cohort were 76.1, 64.5, and 69.4%, respectively. For out-of-field distant metastases, the cumulative intracranial objective response rate (icORR) and intracranial disease control rate (icDCR) reached 52.1 and 64.6%, compared with 81.2 and 97.9% for in-field metastases. The WBRT-boost group exhibited a median OS of 6.6 months, while the SRT group achieved superior 1-year outcomes (OS:79.1%; iDPFS:67.0%; iLPFS:71.8%). Compared with WBRT-boost, SRT showed significantly better local control (iLPFS, P = 0.044) and overall survival (OS, P = 0.036), though distant control (iDPFS, P = 0.086) did not differ significantly. Multivariate analysis identified V12 > 10 cc (HR 12.52, P = 0.011) and female sex (HR 11.66, P = 0.026) as independent prognostic factors. All 12 symptomatic radiation necrosis cases (27.3%) occurred in the SRT group. Logistic regression demonstrated that higher BED3 (HR 57.0, P = 0.009) independently increased sCRN risk, whereas targeted therapy (HR 0.08, P = 0.024) significantly reduced it. HyperArc-based fractionated stereotactic radiotherapy proves safe and feasible for managing brain metastases from lung cancer, achieving effective intracranial tumor control. Compared with WBRT + boost, SRT yields superior therapeutic outcomes despite requiring careful monitoring for symptomatic radiation necrosis. Further investigations should examine combined approaches incorporating targeted agents and optimized dose distribution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.